ENGN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
32.0M
+2.5%
31.2M
-21.0%
39.5M
+31.8%
29.9M
+10.4%
27.1M
R&D
22.2M
-0.3%
22.3M
-29.8%
31.7M
+40.5%
22.6M
+11.7%
20.2M
SG&A
9.8M
+9.4%
8.9M
+15.1%
7.8M
+5.2%
7.4M
+6.6%
6.9M
Operating Income
-31968000
-2.5%
-31185000
+21.0%
-39481000
-31.8%
-29947000
-10.4%
-27124000
EBITDA
-31788000
-2.6%
-30996000
+21.1%
-39310000
-31.8%
-29817000
-10.4%
-27018000
Net Income
-30227000
-1.6%
-29752000
+21.5%
-37880000
-30.7%
-28991000
-12.3%
-25815000
EPS (Basic)
$-0.43
+2.3%
$-0.44
+40.5%
$-0.74
-29.8%
$-0.57
-11.8%
$-0.51
EPS (Diluted)
$-0.43
+2.3%
$-0.44
+40.5%
$-0.74
-29.8%
$-0.57
-11.8%
$-0.51
Shares (Diluted)
69.7M
+3.7%
67.3M
+30.9%
51.4M
+0.6%
51.1M
+0.2%
51.0M
enGene Therapeutics (ENGN) โ€” Financials